Investors' Impax Drug Price-Fixing Suit Fails Again

Law360 (August 12, 2019, 10:54 PM EDT) -- A California federal judge on Monday again dismissed a shareholder suit alleging generic-drug maker Impax Laboratories Inc. failed to disclose to investors a federal investigation over possibly collusive market activity, finding the shareholders failed to remedy the issues that got their complaint tossed the first time around.

This time, U.S. District Judge Haywood S. Gilliam Jr. did not grant leave to amend the complaint led by a New York pension fund for hotels accusing Impax of colluding with its competitors to fix the prices of two generic drugs used to treat central nervous system disorders.

"Plaintiff's theory relies on the unreasonable...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS